Background: The reported immunomodulatory effects of transfusion raise
concern about the potential for virus activation and tumor growth in
human immunodeficiency virus (HIV)-infected patients. In the absence o
f ''standards'' of transfusion practice for such patients, a survey of
transfusion policies among institutions specializing in the care of H
IV-infected patients was performed to delineate current practices. Stu
dy Design and Methods: A survey developed by the Transfusion Practices
Committee of the American Association of Blood Banks was sent to 47 A
IDS clinical trial units and 14 regional hemophilia centers in North A
merica, Results: Forty-three percent of centers completed the survey.
Most centers observed more than 200 HIV-infected patients each. The ke
y findings were that 1) 81 percent of centers used identical red cell
transfusion criteria for HIV-infected and noninfected patients; 2) 52
percent used recombinant human erythropoietin as initial treatment for
zidovudine-induced anemia, while 46 percent used recombinant human er
ythropoietin for anemia not associated with zidovudine; 3) 35 percent
of centers used white cell-reduced blood components in lieu of cytomeg
alovirus (CMV)-seronegative components when administering transfusion(
s) to CMV-seronegative patients; 4) 27 percent gamma-radiated cellular
components, but no case of graft-versus-host disease had been observe
d; 5) >85 percent of centers used monoclonal factor VIII for pediatric
and adult hemophiliacs infected with HIV; 6) approximately one-third
of centers routinely white cell-reduced cellular components; and 7) th
e most common reasons for white cell reduction included reduction of f
ebrile reactions and CMV risk, reduction of platelet alloimmunization,
and delay of immunomodulatory consequences of transfusion. Conclusion
: There is marked heterogeneity in transfusion practice for HIV-infect
ed patients, Modification of cellular components to achieve different
objectives is routine in many centers.